TrialNet T1D Risk Screening
TrialNet offers risk screening to identify individuals in the early stages of T1D, so they can try to change the course of the disease. Each participant learns about their individual risk and helps us learn more about T1D. If you have a relative with T1D, you’re in a unique position to advance important T1D research.
Know your T1D risk
A small blood sample collected at the event (or a test kit you can take with you) will allow us to detect your risk of developing T1D. We look for diabetes-related autoantibodies that can be detected years before symptoms appear.
The results are important.
Detecting future risk is important. Depending on your screening results, you may be eligible to join a TrialNet prevention study exploring treatments aiming stop disease progression, or you may be eligible for monitoring.
Getting screened is easy.
A TrialNet representative will collect a small blood sample (less than 2 teaspoons), or you can take an in-home test kit to collect your sample via fingerstick. Samples are sent to a laboratory for analysis. We will notify you of your results in about 4-6 weeks (8 weeks outside the U.S.). Please note that due to COVID-19, there may be a delay in receiving your TrialNet Pathway to Prevention Screening results after participating. If your test results detect two or more diabetes-related autoantibodies, you will be asked to schedule a follow-up visit to see if you are eligible for a prevention study.
Who can get screened?
TrialNet T1D risk screening is offered to anyone between the ages of 2.5 and 45 with a sibling, child, or parent with type 1 diabetes OR anyone between the ages of 2.5 and 20 with a sibling, child, parent, cousin, uncle, aunt, niece, nephew, grandparent or half-sibling with type 1 diabetes. Please note: TrialNet no longer offers rescreening to children who initially test negative for autoantibodies.